Quantcast

Valeant Pharmaceuticals International (VRX) Is Up After Guidance Increase


Shutterstock photo


(RTTNews.com) - Valeant Pharmaceuticals International ( VRX ) reported first quarter results Tuesday morning and also increased its full year revenue guidance to between $8.15 billion and $8.35 billion from the prior outlook of $8.10 billion to $8.30 billion.

The company also announced that it will change its name to Bausch Health Companies Inc., effective in July 2018.

Valeant gapped open sharply higher this morning and is now up 2.34 at $20.50. The stock has risen to over a 3-month high.


Read the original article on RTTNews (http://www.rttnews.com/2892383/valeant-pharmaceuticals-international-vrx-is-up-after-guidance-increase.aspx)


For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks , Politics
Referenced Symbols: VRX


More from RTT News

Subscribe






See All RTT news









Research Brokers before you trade

Want to trade FX?